By: IPP Bureau
Last updated : December 29, 2025 8:23 pm
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Global pharma giant Lupin has partnered with China's Gan & Lee Pharmaceuticals for exclusive rights to market and distribute Bofanglutide, a new fortnightly GLP-1 drug for diabetes/weight loss, expanding its metabolic disease portfolio
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals.
As a potential first-in-class global treatment, Bofanglutide offers a significant convenience advantage with fortnightly (once every two weeks) dosing, compared to the weekly injections required by current alternatives. Clinical data indicates that the drug effectively reduces blood glucose and body weight, with weight loss results that meet or exceed existing GLP-1 therapies while maintaining a consistent safety profile.
Obesity is anticipated to develop into a significant health crisis in India, with approximately 174 million adults classified as overweight and around 50 million as obese. Diabetes is already considered an epidemic, with approximately 90 million adults affected by the condition. Under the terms of the agreement, Lupin will have exclusive rights to commercialize and distribute Bofanglutide in India.
Nilesh Gupta, Managing Director, Lupin, said, "We are committed to offering the best solutions for managing chronic metabolic diseases like Diabetes, and addressing Obesity is one of the most urgent global health challenges. This partnership demonstrates our strategic focus on the GLP-1 class of drugs and highlights our dedication to delivering high-quality, innovative therapies for our patients."
Rajeev Sibal, President - India Region Formulations, Lupin, said, "Bofanglutide offers a significant advantage with its convenient fortnightly dosing, thus reducing the number of injections by 50% while delivering outcomes and clinically proven efficacy that matches or surpasses existing weekly formulations. This strategic alliance marks a pivotal step in strengthening Lupin's leadership in metabolic health, expanding our innovative portfolio, and reaffirming our commitment to delivering transformative solutions."
Gan & Lee Executive Vice President & Chief Commercial Officer (EVP & CCO) Kai Du and Key Accounts Director, Dr Dhaval Soneji commented and believed: "On the heels of the Latin American exclusive agreement signed in November, this new partnership with Lupin for the Indian market further underscores Gan & Lee's rapid global strategic advancement. Our goal is to provide superior treatment options for patients with metabolic diseases worldwide, while showcasing the value of Chinese biopharmaceutical innovation on the global stage."